Catalent 3Q Revenues: $627.9 million (+18%) 3Q Earnings: $19.0 million (-27%) YTD Revenues: $1.8 billion (+18%) YTD Earnings: $0.9 million (earnings were $48 million YTD17) Comments: Revenue from the Softgel Technologies segment was $228.5 million in the quarter, up 9% primarily attributable to the February 2017 Accucaps acquisition. Revenue from the Drug Delivery Solutions segment was $313.6 million, an increase of 34%. This growth was primarily attributable to the Cook Pharmica acquisitio...